

Special Issue

Mechanisms of mRNA Translation in Pancreatic Cancer

Message from the Guest Editor

We are seeking original research articles that explore the mechanistic aspects of mRNA translation control and its impact on the development and progression of pancreatic cancer. Specifically, we encourage studies that investigate the role of aberrant translation regulation in oncogenesis and the overexpression of oncogenic proteins in pancreatic cancer cells. We also welcome studies that elucidate the signaling pathways and molecular mechanisms involved in mRNA translation regulation and the effects of changes in the tumor microenvironment on translation in pancreatic cancer. Additionally, we are interested in studies that focus on developing novel therapeutic strategies for pancreatic cancer by targeting the translation machinery, such as inhibiting the activity of translation initiation factors or targeting specific mRNAs overexpressed in pancreatic cancer cells. The scope of this Special Issue is broadly on the mechanisms of mRNA translation in pancreatic cancer, and it involves a range of disciplines and techniques, including molecular biology, biochemistry, cancer cell biology, and therapeutics.

Guest Editor

Dr. Kamini Singh

Department of Molecular Pharmacology, Albert Einstein College of Medicine, Albert Einstein Cancer Center, Bronx, NY 10461, USA

Deadline for manuscript submissions

closed (15 December 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/170682

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)